A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression.
about
Transcriptional Targeting in Cancer Gene TherapyVaccine To Confer to Nonhuman Primates Complete Protection against Multistrain Ebola and Marburg Virus InfectionsNovel system uses probasin-based promoter, transcriptional silencers and amplification loop to induce high-level prostate expressionAdvances in preclinical investigation of prostate cancer gene therapy.Molecular imaging of biological gene delivery vehicles for targeted cancer therapy: beyond viral vectors.Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector.Transcription initiation activity of adenovirus left-end sequence in adenovirus vectors with e1 deletedHighly specific transgene expression mediated by a complex adenovirus vector incorporating a prostate-specific amplification feedback loop.Gene therapy and immunotherapy of prostate cancer: adenoviral-based strategies.The present and future for gene and viral therapy of directly accessible prostate and squamous cell cancers of the head and neck.Gene therapy vector design strategies for the treatment of cancer.Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report.Death receptors as targets for anti-cancer therapy.Targeting the Fas/FasL signaling pathway in cancer therapy.Multivalent and Multipathogen Viral Vector Vaccines.Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.Adenovirus-mediated FasL gene transfer into human gastric carcinoma.Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector.Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression.Targeting proliferating tumor cells via the transcriptional control of therapeutic genes.Nonviral genetic transfer of Fas ligand induced significant growth suppression and apoptotic tumor cell death in prostate cancer in vivo.
P2860
Q24791038-4DCFB0FE-4362-432E-B152-C906A5E33141Q27485491-31F9654F-0261-4F84-A9DC-ECD807FD42EEQ33273469-DE5D41EF-F175-429E-9374-B463F94D580AQ33677054-4F38DABD-09D3-4853-8DB1-D7C20A12741DQ33704231-16ED54D8-90B9-45BB-A523-4A2376F79A75Q33768646-B87816D0-0A18-4D15-A027-9BEBB031ECEEQ34464125-A39DBC2A-5115-48DE-8D0A-2B45A937586FQ35695549-D5D46301-B76F-4B74-868E-CFBDD55C6884Q36258513-A20B5133-4153-4634-A0B6-EB76C8B72C75Q36429405-4A2A927F-B820-44A1-B0D4-C256867276FFQ36429492-A88AAA19-8883-4AB0-BF72-961106ED8BA1Q36501180-EB1122E7-C54F-4335-AD7F-DC5816E3D130Q37390893-349E76DB-AAFC-4234-8CCE-2527010347DDQ37975245-B53B0B95-29CE-46DB-AE82-CA1B6998AA4BQ38830323-31D1AB28-6D42-43B2-8963-21FB35A25CD1Q40311630-E6286EF7-556F-4802-932E-825753A28D68Q40411306-8BB827C2-207B-4518-B6B9-F7C5FBCADDACQ40618698-EB3B8582-42C2-40AD-BAFE-D8AC136071A0Q40657886-B33500CC-0CA7-4274-8FE0-76E5766FC3F6Q45274551-8613D11C-7CEE-4060-B67C-4C20D50A12FAQ45858785-778451AC-547D-40D8-95DD-93E55A6C45B6
P2860
A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
A complex adenovirus vector th ...... acycline-regulated expression.
@en
A complex adenovirus vector th ...... acycline-regulated expression.
@nl
type
label
A complex adenovirus vector th ...... acycline-regulated expression.
@en
A complex adenovirus vector th ...... acycline-regulated expression.
@nl
prefLabel
A complex adenovirus vector th ...... acycline-regulated expression.
@en
A complex adenovirus vector th ...... acycline-regulated expression.
@nl
P2093
P356
P1433
P1476
A complex adenovirus vector th ...... acycline-regulated expression.
@en
P2093
Rubinchik S
P304
P356
10.1006/MTHE.2001.0478
P577
2001-11-01T00:00:00Z